J Knäblein
John Wiley & Sons
e druk, 2005
9783527311842
Modern Biopharmaceuticals – Design, Development and Optimization 4V Set +CD
Design, Development and Optimization 4 Volume Set
Specificaties
Gebonden, 2022 blz.
|
Engels
John Wiley & Sons |
e druk, 2005
ISBN13: 9783527311842
Rubricering
Verwachte levertijd ongeveer 16 werkdagen
Samenvatting
The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.
With over one third of all pipe–line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.
Specificaties
Inhoudsopgave
Volume 1
<br />
<br /> INTRODUCTION
<br /> PART I: BIOPHARMACEUTICALS USED IN MOLECULAR MEDICINE
<br /> Genes & genomes – correlation between genes, diseases & biopharmaceuticals
<br /> siRNA – the magic bullet & other gene therapeutical approaches
<br /> Mobilis in mobile – human embryonic stem cells & other sources for cell therapy
<br />
<br />
<br /> Volume 2
<br />
<br /> PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION
<br /> The clotting cascade – lysis, coagulation & a fine–tuned balance
<br /> Errare humanum est – what causes cancer & how to selectively fight tumors
<br /> Mundus vult decipi – high mutation rates of HIV & new paradigms for treatment
<br /> PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS
<br /> Citius, altius, fortius – acceleration by high throughput & ultra–HT
<br /> Early target validation – knock–out mice & more
<br /> Revolution by evolution – rational design for desire & the scientific art of optimization
<br />
<br />
<br /> Volume 3
<br />
<br /> PART IV: PRODUCTION OF BIOPHARMACEUTICALS
<br /> The industry′s workhorses – mammalian expression systems
<br /> A ripe and blooming market – biopharmaceuticals from transgenic animals & plants
<br /> Alea non iacta est – improving established expression systems
<br /> When success raises its ugly head – outsourcing to uncork the capacity bottleneck
<br /> PART V: BIOPHARMACEUTICALS USED FOR DIAGNOSTICS AND IMAGING
<br /> From hunter to craftsman – engineering antibodies with nature′s universal toolbox
<br /> Find, fight & follow – target–specific troica from Mother Nature′s Pharmacopoiea
<br /> Getting insight – sense the urgency for early diagnostics
<br />
<br />
<br /> Volume 4
<br />
<br /> PART VI: ADVANCED APPLICATION ROUTES FOR BIOPHARMACEUTICALS
<br /> Getting inside – quest for the best & how to improve delivery
<br /> Pathfinder – new ways for peptides, proteins & Co
<br /> Via mala – the stony road of DNA delivery: back–pack, feed–back & pay–back
<br /> Getting beyond – rocket science & science fiction
<br /> PART VII: FROM TRANSCRIPTION TO PRESCRIPTION
<br /> Opening the therapeutic window – between systemic toxicity & lack of efficacy
<br /> Happy end – claim to fame & approval
<br /> PART VIII: FROM BENCH TO BEDSIDE –
<br /> THE AFTERMATHS
<br /> Think big & dealmaking for growth – global changes in the health–care sector
<br /> News & views – quo vadis, biopharmaceuticals?
<br /> Small molecules – light at the end of the tunnel or back to the roots?
<br />
<br /> INTRODUCTION
<br /> PART I: BIOPHARMACEUTICALS USED IN MOLECULAR MEDICINE
<br /> Genes & genomes – correlation between genes, diseases & biopharmaceuticals
<br /> siRNA – the magic bullet & other gene therapeutical approaches
<br /> Mobilis in mobile – human embryonic stem cells & other sources for cell therapy
<br />
<br />
<br /> Volume 2
<br />
<br /> PART II: BIOPHARMACEUTICALS AND THEIR MODE OF ACTION
<br /> The clotting cascade – lysis, coagulation & a fine–tuned balance
<br /> Errare humanum est – what causes cancer & how to selectively fight tumors
<br /> Mundus vult decipi – high mutation rates of HIV & new paradigms for treatment
<br /> PART III: IMPROVING THE DEVELOPMENT OF BIOPHARMACEUTICALS
<br /> Citius, altius, fortius – acceleration by high throughput & ultra–HT
<br /> Early target validation – knock–out mice & more
<br /> Revolution by evolution – rational design for desire & the scientific art of optimization
<br />
<br />
<br /> Volume 3
<br />
<br /> PART IV: PRODUCTION OF BIOPHARMACEUTICALS
<br /> The industry′s workhorses – mammalian expression systems
<br /> A ripe and blooming market – biopharmaceuticals from transgenic animals & plants
<br /> Alea non iacta est – improving established expression systems
<br /> When success raises its ugly head – outsourcing to uncork the capacity bottleneck
<br /> PART V: BIOPHARMACEUTICALS USED FOR DIAGNOSTICS AND IMAGING
<br /> From hunter to craftsman – engineering antibodies with nature′s universal toolbox
<br /> Find, fight & follow – target–specific troica from Mother Nature′s Pharmacopoiea
<br /> Getting insight – sense the urgency for early diagnostics
<br />
<br />
<br /> Volume 4
<br />
<br /> PART VI: ADVANCED APPLICATION ROUTES FOR BIOPHARMACEUTICALS
<br /> Getting inside – quest for the best & how to improve delivery
<br /> Pathfinder – new ways for peptides, proteins & Co
<br /> Via mala – the stony road of DNA delivery: back–pack, feed–back & pay–back
<br /> Getting beyond – rocket science & science fiction
<br /> PART VII: FROM TRANSCRIPTION TO PRESCRIPTION
<br /> Opening the therapeutic window – between systemic toxicity & lack of efficacy
<br /> Happy end – claim to fame & approval
<br /> PART VIII: FROM BENCH TO BEDSIDE –
<br /> THE AFTERMATHS
<br /> Think big & dealmaking for growth – global changes in the health–care sector
<br /> News & views – quo vadis, biopharmaceuticals?
<br /> Small molecules – light at the end of the tunnel or back to the roots?